Latest Breaking News On - Prometheus labs - Page 3 : comparemela.com
Introducing ENVOY Network
prnewswire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.co.uk Daily Mail and Mail on Sunday newspapers.
Trade Secret Litigation Boom Continues - Intellectual Property
mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.
Immunotherapy combination improves outcomes in advanced kidney cancer 4 March
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Date Time
Dana-Farber research supports FDA approval for immunotherapy combination in advanced kidney cancer
Combination of nivolumab and cabozantinib found to significantly improve progression-free survival and reduced the risk of death versus sunitinib in previously untreated patients with advanced kidney cancer
An immunotherapy agent combined with a tyrosine kinase inhibitor drug whose clinical testing as a first-line treatment in advanced kidney cancer was led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, has become a standard therapy.
The combination of nivolumab (OPDIVO
®) and cabozantinib (CABOMETYX
®) was approved today by the U.S. Food and Drug Administration (FDA) as a first-line treatment for patients with advanced renal cell carcinoma (RCC). The approval is based on results from CheckMate -9ER, a phase 3 trial evaluating the combination compared to sunitinib, a single agent treatment.